Everolimus-related unilateral abdominal lymphedema in a renal
cancer patient A case report

J 2020

Everolimus-related unilateral abdominal lymphedema in a renal cancer patient A case report

HALÁMKOVÁ, Jana, Tomáš KAZDA, Dagmar ADAMKOVA-KRAKOROVA, Sylva RYBNÍČKOVÁ, Igor KISS et. al.

Basic information

Original name

Everolimus-related unilateral abdominal lymphedema in a renal cancer patient A case report

Authors

HALÁMKOVÁ, Jana (203 Czech Republic, guarantor, belonging to the institution), Tomáš KAZDA (203 Czech Republic, belonging to the institution), Dagmar ADAMKOVA-KRAKOROVA (203 Czech Republic), Sylva RYBNÍČKOVÁ (203 Czech Republic), Igor KISS (203 Czech Republic, belonging to the institution) and Regina DEMLOVÁ (203 Czech Republic, belonging to the institution)

Edition

Medicine, Philadelphia, Lippincott Williams & Wilkins, 2020, 0025-7974

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30218 General and internal medicine

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 1.889

RIV identification code

RIV/00216224:14110/20:00117214

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1097/MD.0000000000022634

UT WoS

000589394700033

Keywords in English

abdominal lymphedema; case report; everolimus-related adverse event; mammalian target of rapamycin inhibitors; renal cancer; unilateral lymphedema

Abstract

V originále

Rationale: Unilateral manifestation of lymphedema during everolimus therapy has been described only rarely, mostly in transplant recipients. Patient concerns: We report the first case of a patient who developed unilateral abdominal lymphedema, during a short period of everolimus treatment for renal cancer. Diagnosis: The abdominal asymmetry occurred only on the right side of the abdomen, neither ultrasound nor CT scan detected ascites but showed enlargement of the abdominal wall. The Naranjo Adverse Drug Reaction Probability scale was evaluated, in this case, a score of 6 indicated a probable adverse reaction to everolimus. Interventions: Discontinuation of everolimus therapy led to immediate alleviation and reduction of the lymphedema, with worsening once again after initiating retreatment with everolimus at a reduced dose. Outcomes: The patient's lymphedema recovered after discontinuation of everolimus. Lessons: This rare case demonstrates the importance of the selection of mammalian target of rapamycin inhibitors using caution, especially for patients with a high risk of developing lymphedema.

Links

LM2018128, research and development project

Name: Český národní uzel Evropské sítě infrastruktur klinického výzkumu (Acronym: CZECRIN)

Investor: Ministry of Education, Youth and Sports of the CR

Citovat

HALÁMKOVÁ, Jana, Tomáš KAZDA, Dagmar ADAMKOVA-KRAKOROVA, Sylva RYBNÍČKOVÁ, Igor KISS and Regina DEMLOVÁ. Everolimus-related unilateral abdominal lymphedema in a renal cancer patient A case report. Medicine. Philadelphia: Lippincott Williams & Wilkins, 2020, vol. 99, No 42, p. 1-4. ISSN 0025-7974. Available from: https://dx.doi.org/10.1097/MD.0000000000022634.

@article{1703256,
   author = {Halámková, Jana and Kazda, Tomáš and AdamkovaandKrakorova, Dagmar and Rybníčková, Sylva and Kiss, Igor and Demlová, Regina},
   article_location = {Philadelphia},
   article_number = {42},
   doi = {http://dx.doi.org/10.1097/MD.0000000000022634},
   keywords = {abdominal lymphedema; case report; everolimus-related adverse event; mammalian target of rapamycin inhibitors; renal cancer; unilateral lymphedema},
   language = {eng},
   issn = {0025-7974},
   journal = {Medicine},
   title = {Everolimus-related unilateral abdominal lymphedema in a renal cancer patient A case report},
   url = {https://journals.lww.com/md-journal/Fulltext/2020/10160/Everolimus_related_unilateral_abdominal_lymphedema.33.aspx},
   volume = {99},
   year = {2020}
}

TY  - JOUR
ID  - 1703256
AU  - Halámková, Jana - Kazda, Tomáš - Adamkova-Krakorova, Dagmar - Rybníčková, Sylva - Kiss, Igor - Demlová, Regina
PY  - 2020
TI  - Everolimus-related unilateral abdominal lymphedema in a renal cancer patient A case report
JF  - Medicine
VL  - 99
IS  - 42
SP  - 1-4
EP  - 1-4
PB  - Lippincott Williams & Wilkins
SN  - 00257974
KW  - abdominal lymphedema
KW  - case report
KW  - everolimus-related adverse event
KW  - mammalian target of rapamycin inhibitors
KW  - renal cancer
KW  - unilateral lymphedema
UR  - https://journals.lww.com/md-journal/Fulltext/2020/10160/Everolimus_related_unilateral_abdominal_lymphedema.33.aspx
L2  - https://journals.lww.com/md-journal/Fulltext/2020/10160/Everolimus_related_unilateral_abdominal_lymphedema.33.aspx
N2  - Rationale: Unilateral manifestation of lymphedema during everolimus therapy has been described only rarely, mostly in transplant recipients. Patient concerns: We report the first case of a patient who developed unilateral abdominal lymphedema, during a short period of everolimus treatment for renal cancer. Diagnosis: The abdominal asymmetry occurred only on the right side of the abdomen, neither ultrasound nor CT scan detected ascites but showed enlargement of the abdominal wall. The Naranjo Adverse Drug Reaction Probability scale was evaluated, in this case, a score of 6 indicated a probable adverse reaction to everolimus. Interventions: Discontinuation of everolimus therapy led to immediate alleviation and reduction of the lymphedema, with worsening once again after initiating retreatment with everolimus at a reduced dose. Outcomes: The patient's lymphedema recovered after discontinuation of everolimus. Lessons: This rare case demonstrates the importance of the selection of mammalian target of rapamycin inhibitors using caution, especially for patients with a high risk of developing lymphedema.
ER  -

HALÁMKOVÁ, Jana, Tomáš KAZDA, Dagmar ADAMKOVA-KRAKOROVA, Sylva RYBNÍČKOVÁ, Igor KISS and Regina DEMLOVÁ. Everolimus-related unilateral abdominal lymphedema in a renal cancer patient A case report. \textit{Medicine}. Philadelphia: Lippincott Williams \&{} Wilkins, 2020, vol.~99, No~42, p.~1-4. ISSN~0025-7974. Available from: https://dx.doi.org/10.1097/MD.0000000000022634.

Detailed Information on Publication Record